Brief Report: Risk of Gastrointestinal Perforation Among Rheumatoid Arthritis Patients Receiving Tofacitinib, Tocilizumab, or Other Biologic Treatments

Arthritis and Rheumatology

Volumn 68, Issue 11, 2016, Pages 2612-2617

  Xie, Fenglong ^a   Yun, Huifeng ^a   Bernatsky, Sasha ^b   Curtis, Jeffrey R ^a  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ABATACEPT; ADALIMUMAB; BIOLOGICAL PRODUCT; CERTOLIZUMAB PEGOL; ETANERCEPT; GOLIMUMAB; INFLIXIMAB; PREDNISONE; RITUXIMAB; TOCILIZUMAB; TOFACITINIB; TUMOR NECROSIS FACTOR INHIBITOR; ANTIRHEUMATIC AGENT; GLUCOCORTICOID; MONOCLONAL ANTIBODY; PIPERIDINE DERIVATIVE; PYRIMIDINE DERIVATIVE; PYRROLE DERIVATIVE; TUMOR NECROSIS FACTOR;

ADULT; AGE; ARTICLE; COHORT ANALYSIS; DIGESTIVE SYSTEM PERFORATION; DIVERTICULITIS; DRUG EXPOSURE; FEMALE; FOLLOW UP; HUMAN; INCIDENCE; LOWER GASTROINTESTINAL TRACT PERFORATION; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; RISK FACTOR; UPPER GASTROINTESTINAL TRACT PERFORATION; AGED; ANTAGONISTS AND INHIBITORS; ARTHRITIS, RHEUMATOID; ESOPHAGEAL PERFORATION; FACTUAL DATABASE; GASTROESOPHAGEAL REFLUX; INTESTINAL PERFORATION; MEDICARE; PEPTIC ULCER; PROPORTIONAL HAZARDS MODEL; UNITED STATES;

ABATACEPT; ADULT; AGE FACTORS; AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BIOLOGICAL PRODUCTS; DATABASES, FACTUAL; DIVERTICULITIS; ESOPHAGEAL PERFORATION; FEMALE; GASTROESOPHAGEAL REFLUX; GLUCOCORTICOIDS; HUMANS; INCIDENCE; INTESTINAL PERFORATION; MALE; MEDICARE; MIDDLE AGED; PEPTIC ULCER; PIPERIDINES; PREDNISONE; PROPORTIONAL HAZARDS MODELS; PYRIMIDINES; PYRROLES; RISK FACTORS; RITUXIMAB; TUMOR NECROSIS FACTOR-ALPHA; UNITED STATES;

EID: 84992623468     PISSN: 23265191     EISSN: 23265205     Source Type: Journal    
DOI: 10.1002/art.39761     Document Type: Article

References (15)

1. Lanas A, Carrera-Lasfuentes P, Arguedas Y, Garcia S, Bujanda L, Calvet X, et al. Risk of upper and lower gastrointestinal bleeding in patients taking nonsteroidal anti-inflammatory drugs, antiplatelet agents, or anticoagulants. Clin Gastroenterol Hepatol 2015;13:906–12.e2.
2. Gout T, Ostor AJ, Nisar MK. Lower gastrointestinal perforation in rheumatoid arthritis patients treated with conventional DMARDs or tocilizumab: a systematic literature review. Clin Rheumatol 2011;30:1471–4.
3. Curtis JR, Xie F, Chen L, Spettell C, McMahan RM, Fernandes J, et al. The incidence of gastrointestinal perforations among rheumatoid arthritis patients. Arthritis Rheum 2011;63:346–51.
4. Laine L, Connors LG, Reicin A, Hawkey CJ, Burgos-Vargas R, Schnitzer TJ, et al. Serious lower gastrointestinal clinical events with nonselective NSAID or coxib use. Gastroenterology 2003;124:288–92.
5. Lanas A, Garcia-Rodriguez LA, Arroyo MT, Gomollon F, Feu F, Gonzalez-Perez A, et al. Risk of upper gastrointestinal ulcer bleeding associated with selective cyclo-oxygenase-2 inhibitors, traditional non-aspirin non-steroidal anti-inflammatory drugs, aspirin and combinations. Gut 2006;55:1731–8.
6. Schiff MH, Kremer JM, Jahreis A, Vernon E, Isaacs JD, van Vollenhoven RF. Integrated safety in tocilizumab clinical trials. Arthritis Res Ther 2011;13:R141.
7. Kim SY, Servi A, Polinski JM, Mogun H, Weinblatt ME, Katz JN, et al. Validation of rheumatoid arthritis diagnoses in health care utilization data. Arthritis Res Ther 2011;13:R32.
8. Curtis JR, Chen SY, Werther W, John A, Johnson DA. Validation of ICD-9-CM codes to identify gastrointestinal perforation events in administrative claims data among hospitalized rheumatoid arthritis patients. Pharmacoepidemiol Drug Saf 2011;20:1150–8.
9. Yang D, Dalton JE. A unified approach to measuring the effect size between two groups using SAS. In: Proceedings of the SAS Global Forum 2012 Conference. Cary (NC): SAS Institute; 2012.
10. Lin DY, Wei LJ. The robust inference for the proportional hazards model. J Am Stat Assoc 1989;84:1074–8.
11. Strangfeld A, Richter A, Herzer P, Rockwitz K, Demary W, Aringer M, et al. Risk for lower intestinal perforations in RA patients treated with tocilizumab in comparison to treatment with TNF inhibitors, rituximab, abatacept or conventional synthetic Dmards [abstract]. Arthritis Rheumatol 2015;67 Suppl 10. URL: http://acrabstracts.org/abstract/risk-for-lower-intestinal-perforations-in-ra-patients-treated-with-tocilizumab-in-comparison-to-treatment-with-tnf-inhibitors-rituximab-abatacept-or-conventional-synthetic-dmards/.
12. Myasoedova E, Matteson EL, Talley NJ, Crowson CS. Increased incidence and impact of upper and lower gastrointestinal events in patients with rheumatoid arthritis in Olmsted County, Minnesota: a longitudinal population-based study. J Rheumatol 2012;39:1355–62.
13. Fleischmann R, Rubbert-Roth A, Combe B, vanLunen B, Andrews P, de Longueville M. Gastrointestinal perforation with certolizumab PEGOL [abstract]. Ann Rheum Dis 2013;71 Suppl 3:370.
14. Lee EB, Curtis JR, Riese R, Connell CA, Chew R, Boy MG, et al. Tofacitinib, an oral Janus kinase inhibitor: analysis of gastrointestinal adverse events across the rheumatoid arthritis clinical program [abstract]. Arthritis Rheum 2013;65 Suppl:S191.
15. Chan FK, Cryer B, Goldstein JL, Lanas A, Peura DA, Scheiman JM, et al. A novel composite endpoint to evaluate the gastrointestinal (GI) effects of nonsteroidal antiinflammatory drugs through the entire GI tract. J Rheumatol 2010;37:167–74.